Kymera Therapeutics, Inc. announced on October 23, 2024, that new preclinical data from its innovative Targeted Protein Degradation (TPD) platform would be presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The presentations included new data on its preclinical biomarker-based approach for KT-253, an MDM2 degrader.
Research efforts identified patient populations sensitive to the KT-253 degrader mechanism and defined biomarkers associated with an acute apoptotic response in tumors. Using a machine learning framework, results identified tumor types sensitive to KT-253, consistent with preclinical and early clinical findings, including acute myeloid leukemia (AML), neuroendocrine tumors, and subsets of solid tumors.
The company also presented a poster highlighting its platform capabilities and the use of targeted protein degradation to provide improved potency and selectivity for CDK2. CDK2 is a cell cycle regulator and key protein involved in several cancers. KT-253 is currently in a Phase 1 clinical trial for solid tumors and hematological malignancies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.